While some physicians prefer the autonomy of working in private practice, working with a major health system, especially an academic one, can afford several opportunities to specialists. From more access to resources and research, to a focus on cutting-edge patient care, there are many pros to the practice setting.Benjamin Levy III, MD, a gastroenterologist from University of Chicago Medicine, told Becker’s what he enjoys most about practicing at the academic medical center.
Author: Abhay Panchal
New research highlights an increased risk of colorectal cancer (CRC) in patients with both nonadvanced and advanced adenomas detected during colonoscopy. The study, leveraging data from the Minnesota Colon Cancer Control Study, found that individuals with adenomas had a greater risk of developing CRC compared to those with no adenomas, with advanced adenomas also linked to increased CRC mortality and all-cause mortality. The findings reinforce the importance of surveillance colonoscopy, particularly for those with advanced adenomas, to ensure early detection and intervention. The article gives insights on the necessity of frequent CRC screening and the implications for long-term patient outcomes.
A new study published in Gastro Hep Advances found that multitarget stool DNA (mt-sDNA) testing for colorectal cancer remains accurate regardless of whether patients are on anticoagulant or antiplatelet medications. Researchers at Mayo Clinic analyzed data from over 11,000 patients and determined that medication use did not significantly impact the test’s positive predictive value (PPV), which stood at 31.4% for detecting advanced adenomas. These findings suggest that patients at risk for cardiovascular events can safely continue their medications while undergoing CRC screening. The article gives insights on the reliability of mt-sDNA testing in real-world settings.
Healthcare mergers and acquisitions (M&A) are expected to surge in 2025 as economic conditions improve and regulatory scrutiny potentially eases. Physician groups considering private equity transactions must weigh the financial benefits against long-term control and operational changes. Law firm Foley & Lardner wrote in a Feb. 10 article published in JD Supra that key factors include preparing for due diligence, securing group consensus, engaging experienced advisors, and addressing compliance risks early to protect deal value. Structuring transactions with favorable tax treatment, indemnification protections, and equity rollovers is critical. With deal volume rising, careful planning will be essential for successful practice…
Scientists at NUS have developed Gut-Microbiome on a Chip (GMoC)—a 3D microgut model that mimics human intestines, allowing researchers to study gut microbes and their role in health and disease more accurately. The chip replicates gut structures, oxygen levels, and food movement, making it a scalable, realistic tool for investigating microbial interactions, immune responses, and potential therapeutic targets. Researchers aim to refine and commercialize the technology, paving the way for breakthroughs in gut microbiome research and disease prevention. The article gives insights on how GMoC could transform microbiome studies.
New research on GLP-1 medications, including Ozempic and Wegovy, highlights their far-reaching health benefits beyond weight loss—such as reduced risks of substance use disorders, Alzheimer’s, and clotting issues—while also revealing side effects like nausea, dehydration, and pancreatitis. Physicians emphasize the importance of dosage timing, dietary adjustments, and hydration to minimize complications. Regular check-ins help monitor progress, adjust medications, and address metabolic improvements like resolved hypertension. The article gives insights on optimizing GLP-1 treatments while balancing their risks and benefits.
Amazon is ramping up its healthcare ambitions, competing with Walmart through strategic partnerships and AI-driven solutions. With Teladoc Health and AWS-backed AI healthcare innovations, Amazon is expanding virtual care, chronic disease management, and pharmacy services. Meanwhile, Walmart is leveraging same-day pharmacy delivery, launching drone technology, and enhancing last-mile delivery logistics through Walmart GoLocal. Both retail giants are reshaping healthcare accessibility and convenience, with Amazon focusing on AI-powered care and Walmart enhancing operational efficiency. The article gives insights on their evolving healthcare strategies and market impact.
Dr. Treta Purohit is a trailblazing gastroenterologist, healthcare executive, and digital health innovator, spearheading AI-driven diagnostics, telehealth expansion, and robotic advancements in GI care. With leadership roles at Oshi Health, Endiatx, and San Jose Gastroenterology, she has transformed patient access through virtual GI care, value-based models, and cutting-edge research. A sought-after speaker and advisor, Dr. Purohit’s expertise spans clinical operations, health-tech innovation, and policy advocacy. Now seeking a board role, she aims to shape the future of gastroenterology with strategic AI integration and digital transformation. The article gives insights on her contributions to healthcare innovation and leadership.
Endohepatology is an emerging subspeciality dealing with endoscopic diagnosis and management of liver diseases. Traditionally, the role of endoscopy was limited to management of variceal bleed. However, advancements and innovations in the field of endoscopy have expanded its role, now encompassing a broader spectrum of diagnostic and therapeutic procedures for liver diseases.
Cosmo Pharmaceuticals has appointed Andrea Cherubini as its first Chief AI Officer, signaling a major shift toward AI-driven innovation across its portfolio. Cherubini, who played a key role in the development of GI Genius™, the world’s first AI-powered polyp detection system, will now expand AI applications in gastroenterology, dermatology, and drug discovery. His leadership aims to enhance precision medicine, optimize clinical trials, and accelerate AI-enabled drug development. Cosmo’s CEO emphasized that AI is now a core pillar of the company’s growth strategy, with plans to drive innovation beyond endoscopy.